Compliance

• Advised Takeda on personal data outbound transfer compliance matters

• Advised Chia Tai Tianqing (CTTQ, 01177.HK), a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales and distribution capabilities, on data outbound transfer compliance matters

• Advised CooperVision on compliance matters

• Advised Eccogene, a company focused on discovery and development of translational medicine in metabolic and immune-related diseases, on compliance matters

• Advised Happy Life Tech (HLT) on compliance of its DCT Third Party Compliance Management

• Advised Sumitomo Pharma on compliance management of its pivotal decentralized clinical trial with NMPA, including eCOA data outbound transfer, remote recruitment, remote visit, DTP, remote monitoring, human genetic resources, and other aspects of compliance

• Advised CernerEnviza on compliance of data outbound transfer

• Advised Lianren Digital Health, a healthcare data operator, on medical data compliance matters

• Advised LinkDoc on its IPO and data compliance matters

• Advised Amgen on compliance and training relating to "Compliance Management of Clinical and Data Compliance"

• Advised Drug Information Association (DIA) on personal sensitive data outbound transfer compliance matters

• Advised Leads Biolabs on data outbound transfer standard contract with BeiGene in relation to license and collaboration

• Advised Asieris Pharmaceuticals on data compliance management system

• Advised Lvanitech on compliance of personal medical data

• Advised HistoMed, a third-party pathology center, on data compliance matters

• Advised Genscript on compliance of human genetic resources (HGR), biosafety, data, etc. 

• Advised Johnson & Johnson on GSP compliance matters

• Advised Astellas Pharma China Inc. on CGT compliance matters

• Advised Takeda on restructuring compliance matters of its PRC subsidiaries

• Advised Shanghai Pharmaceutical on CSO compliance and general corporate matters

• Advised Hitachi (China) on compliance matters

• Advised HUAGAI Capital on compliance and general corporate matters

• Advised Hexaell Biotech on compliance matters

• Advised MingSight on compliance of clinical study

• Advised ANEXT, a company that specializes in biomolecular drug carriers Exosomes, on compliance and general corporate matters

• Advised Hope For Rare Foundation, the first non-profit foundation in China that specializes in rare disease research and translational medicine, on compliance and general corporate matters

• Advised Velavigo on compliance and general corporate matters

• Advised Redcloud Biotech, an innovative drugs R&D enterprise that specializes in structural pharmacology, on clinical studies compliance and general corporate matters

• Advised Shanjin Capital on compliance and general corporate matters

• Advised CPIC (China Pacific Insurance (Group) Co Ltd) on compliance matters

• Advised XellSmart bio, a company that specializes in stem cell therapy solutions for degenerative diseases, on compliance and general corporate matters

• Advised East China Electric Power Test & Research Institute on compliance matters

• Advised Motion Magic on compliance and general corporate matters

• Advised Aucta Pharmaceuticals, a R&D enterprise that specializes in CNS, dermatology, and pediatrics, on compliance matters

• Advised Ractigen Therapeutic, an innovative drug R&D enterprise that specializes in RNA activation technology, on reorganization and compliance matters

• Advised Triarm on compliance of its Car- T Cell Therapy business related to Human Genetic Resources Administration Office of China

BD (IP Licensing & Collaboration)

• Advised Beicell Therapeutics, a pharmaceutical enterprise developing off-self cell therapy based on the CiPSC platform, on its IP license-out transactions with Thermo Fisher and STEMCELL Technologies Canada Inc.

• Advised AJ Vaccines A/S on its BD collaboration transactions with Clover Biopharmaceuticals

• Advised Lindmik Pharmaceutical, a high-tech pharmaceutical enterprise focusing on the R&D, production and sales of innovative pharmaceutical preparations, on its IP license-in transactions

• Advised Matwings Technology on its BD collaboration transactions with GeneScience Pharmaceutical

• Advised YIRUI Pharmaceutical Technology, a company focused on small molecule drugs, on its IP license-in transactions

• Advised Help on its IP license-out transactions and general corporate matters

• Advised Zenshine, a company that specializes in small molecule therapeutics in the areas of cancer, viral infection and inflammation, on its collaboration transactions with CSO

• Advised Luye Life Sciences Group Ltd. on its IP license and general corporate matters

• Advised Boan Biotech, a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing, on its IP license and collaboration transactions

• Advised Lide Biote (Lab for Innovated Diagnosis and Experimental Therapeutics) on its IP license and collaboration transactions

• Advised WuXi Biologics on its IP license and collaboration transactions.

• Advised Leads Biolabs on its IP licensing

• Advised Biosion Inc. on its IP licensing and collaboration transactions

• Advised Transcenta Holding Ltd. on its establishment of a R&D joint venture with Alebund Pharmaceuticals, IP licensing, commercialization transactions and subsequent clinical R&D

• Advised N1 Life Inc. on its collaboration transactions

• Advised Oculgen on its collaboration transactions

• Advised Singlomics Biopharma on its license transactions

• Advised Genbase on its licensing and collaboration transactions with IMAB, ADC THERAPEUTICS, etc.

• Advised Innolake on its license-in transactions

• Advised CASI Pharmaceuticals on its license-in transactions

• Advised Haichang Biotech on its licensing and collaboration transactions

• Advised GenEros Biopharma on its license-in transactions

• Advised Hicin Pharmaceutical on its license-in and collaboration transactions

• Advised Tyligand Bioscience on its licensing and collaboration transactions

• Advised Changcheng Med on its license-in and collaboration

• Advised Eluminex Biosciences on a medical device exclusive license-in transactions

• Advised Duality Biotherapeutics on its license-in transactions

• Advised Waterstone on its IP licensing disputes with Onconova

• Advised Hifibio on its IP license-in

• Advised Elpiscience on its IP license-in

• Advised Anwita Bioscience on its IP license-in

• Advised Seindabio on its IP license-in

• Advised Karma Pharmaceuticals on its IP license-in from Harvard University

• Advised Biosense on its IP license-in and negotiation on amendment of license agreement

• Advised TDM on its IP license-in

• Advised Hexaell Biotech on its IP license-in

• Advised DRL Biotech on its IP license-in from a Israeli Biomedical enterprises

• Advised BioCytogen on its IP license-in about animal related items

• Advised BridGene on its product R&D corporation and license option transactions

Pharmaceutical Profession Association

• Advised China Food & Drug Administration Magazine on compliance and general corporate matters

• Advised DIA on compliance and general corporate matters

Transactions of Innovative Drugs, Devices and Medical Care

• Innovative Drugs (including Biotech, CXO, Clinical Laboratory, etc.)

• Advised Benethera (Beijing) Biotechnologies, Inc., a pre-clinical innovative immune cell therapy company, on its financing

• Advised Huitian Jinze on its corporate structuring

• Advised Link Health Group, a company specialized in medical innovation for bone and cartilage, on its restructuring and general corporate matters

• Advised JS InnoPharm, a biotech company focused on discovery and development of innovative small molecule oncology medicines, on its VDD of Series B1 financing

• Advised TandemAI on its M&A with Keypoint Pharmaceutical

• Advised Reistone Biopharma Company Limited, a biopharmaceutical company that specializes in developing novel medicines for immuno-inflammatory diseases, on its restructuring and general corporate matters

• Advised Accuredit Therapeutics, a gene-editing technique enterprise, on its financing and ESOP

• Advised Huagai Capital on its investing in NK Cell, a NK cell R&D enterprise

• Advised Dianei Technology, an innovative medical artificial intelligence enterprise, on its financing, restructuring and general corporate matters

• Advised Haiwang on its investing in EmayGene, a gene therapy drug R&D enterprise

• Advised Genevax, an innovative vaccine R&D enterprise, on its ESOP and daily operation legal compliance

• Advised iRegene, a cell therapy drug R&D enterprise, on its corporate structuring and general corporate services

• Advised NanoTech Pharma Inc. on its corporate structuring

• Advised Innatus Therapeutics Inc. on its red chip corporate structuring and financing

• Advised Biosion, Inc. on its restructuring and other matters

• Advised Minke Pharmaceuticals Technology on its financing and general matters

• Advised Virtu Pharmaco on its corporate structuring and general matters

• Advised Suzhou Langrui Biomedicine on its restructuring related matters

• Advised 3E Bioventures on its investing in a biomedicine enterprise

• Advised Shanghai Haiwang Intellectual Property Equity Investment Fund Center (Limited Partnership) on its investing in Shanghai Neutan Pharmaceutical, a CDMO

• Advised Huagai Capital on its investing in Mind Rank AI, an AI adjuvant drug design platform

• Advised Yizun Biomedicine, an immune cell therapy R&D enterprise, on its financing

• Advised Eminence, a cell culture enterprise, on its financing, ESOP and general corporate matters

• Advised TaiLai Biosciences, a biopsy technology enterprise, on its financing

• Advised CTRIS on its establishment of research center in China and general corporate matters.

• Advised LakeBleu Capital on its investment in Conmed BioSciences, a biotech enterprise.

• Advised VMS on its investment in Eden Biologics, a CDMO

• Advised VMS on its cross-over investment in Zhaoke Ophthalmology, an ophthalmic drug R&D enterprise

• Advised VMS on its cross-over round investment in KindStar Global, a genetic diagnostics enterprise

• Advised Orchid Asia Group on its investment in Beijing City Express, a cold chain logistics enterprise

• Advised BVCF on its investment in United Cell Biotech, a cholera vaccines and growth hormone R&D enterprise

• Advised BVCF on its investment in MicuRx, an antibiotic R&D enterprise

• Advised BVCF on its investment in Teruisi, a bioinnovative drug development and process scaler enterprise

• Advised Drug Farm, a biotech enterprise, on its Series A, Series Pre-B financing and general corporate matters

• Advised Haichang Biotech, a nucleic acid innovative drug R&D enterprise, on its financing and restructuring

• Advised Convalife, an anticancer drug R&D enterprise, on its financing

• Advised Juventas, a Car-T R&D enterprise, on its financing

• Advised ArkBio, an antiviral drug R&D enterprise, on its PE financing

• Advised Harbour BioMed, an immuno-oncology and immune diseases R&D enterprise, on its Series A financing

• Advised dMed, a CRO, on its corporate restructuring and financing

• Advised ABclonal Tech, a biological reagent R&D enterprise, on its investment in Yurogen

• Advised Novast Pharmaceuticals, a Nantong-based FDA-approved drug manufacturer, on its restructuring

• Advised Tissuebank Gene Biotech, a clinical laboratory organization, on its PE financing

• Advised OBiO, a gene therapy drug incubation enterprise, on its PE financing

• Advised Phaeno Thera, a biotech enterprise, on its MAH entrusting drug production and financing

• Advised InxMed, a biotech enterprise, on its financing

• Advised Duality Biotherapeutics, a biotech enterprise, on its Series seed, A and B financing from 6 Dimensions Capital, Wuxi Biologics and Lilly Asia

• Advised Immuneonco (CD47) on its Series B and cross-over financing

• Advised 3DMed on its financing and restructuring

• Advised BioCytogen, an animal customization, reproduction and supply enterprise, on its Series C financing, Series D financing, ESOP, investment and restructuring

• Advised CASI Pharmaceuticals, a biotech enterprise, on its investment and ATM financing in public market

• Advised Eubulus Biotherapeutics, a biotech enterprise, on its Series seed and Series A financing and restructuring

• Advised Asieris Pharmaceuticals, an antineoplastic biotech enterprise, on its financing

• Advised Youhoe Biopharma, an innovative antibody drug R&D enterprise, on its Series B financing

• Advised GenEros Biopharma, an immunity R&D enterprise, on its restructuring, Series A, Series A+ financing

• Advised Karma Pharmaceuticals, a small molecule antibody R&D enterprise, on its Series A financing

• Advised Hifibio, a biotech enterprise, on its set-up of overseas financing structure

• Advised Hope Medicine, a biotech enterprise, on its onshore and offshore restructuring and financing

• Advised Yinuoke, a biotech enterprise for immune disorders caused by tumors, on its restructuring

• Advised Genova and Crestion, growth hormone R&D enterprises, on their restructuring, financing and M&A

• Advised Nantong Kangdao, a healthcare products production and sales enterprise, on its restructuring and Pre-IPO financing

Medical Devices

• Advised WuXi PharmaTech on its investing in Yanzheng Experimental Instrument, a Micro-Reactor R&D enterprise

• Advised Bio-Link, a company focused on the key processing equipment and materials for vaccines, antibodies, cell therapies, on its financing and general corporate matters

• Advised Haiwang on its investing in T&J Bio-engineering, a micro parallel bioreactor R&D enterprise

• Advised Synaptic Medical International on its financing, daily operation legal compliance and capital market matters

• Advised DeepMed on its financing and general corporate matters

• Advised YF Capital on its investment in Nanos Medical, an ENT Solution Provider

• Advised YF Capital on its investment in DiaGreat, an in-vitro diagnostic R&D enterprises

• Advised YF Capital on its investment in Wallaby Medical, a neurointerventional devices R&D enterprise

• Advised LakeBleu Capital on its investment in ZYLOX-TONGBRIDGE, a blood vessel thrombectomy equipment R&D enterprise

• Advised LakeBleu Capital on its investment in HeartCare, a minimally invasive intervention R&D enterprise

• Advised OrchidAsia on its investment in SceneRay, a deep brain stimulation system R&D enterprise

• Advised BVCF on its investment in AI Technology, a clinical imaging equipment R&D enterprise

• Advised Wallaby Medical, a neurointerventional devices R&D enterprise, on its legal due diligence and financing

• Advised AcuVU, an endoscopic R&D enterprise, on its restructuring and financing

• Advised NewMed, an artificial Valve R&D enterprise, on its financing

• Advised WeMed, an angiography instrument manufacturing enterprise, on its financing and general matters

• Advised Reach Surgical, Inc., an advanced surgical device company, on its financing and restructuring

• Advised Shecheng Medical, a dental implant surgery R&D enterprise, on its financing

• Advised Horizon Medical, an assisted reproductive medical device R&D enterprise, on its financing

• Advised VivaLNK, a biological information collection and monitoring enterprise, on its restructuring and financing

• Advised MicroMedTec, a minimally invasive medical device and precision medicine R&D enterprise, on its financing

• Advised EZISURG Medical, a minimally invasive medical device R&D enterprise, on its financing

• Advised Klarity Medical & Equipment, a radiotherapy aids and rehabilitation equipment R&D manufacturer, on its financing

• Advised Hitachi Medical Equipment on its acquisition of a Chinese medical device manufacturer, a large magnetic resonance equipment manufacturer

Medical Care (including Online Healthcare, Hospitals, Nursing Homes, Cord Blood Banks, etc.)

• Advised TaiDoc Health on its financing and general corporate matters

• Advised VMS on its investment in Beijing Qinghe Hospital, Beijing Sunbow O&G Hospital, SEIMC Hospital and other subjects affiliated to Golden Meditech Holdings Limited (HK. 0801)

• Advised VMS on its investment in cord blood banks in Beijing, Guangzhou, Zhejiang and Shandong affiliated to Global Cord Blood Corp (NYSE: CO)

• Advised Orchid Asia Group on its investment in Chaoju Eye Hospital Group

• Advised Ping An Securities on its investment in Hangzhou Kangsheng, an Internet medical enterprise

• Advised Wuhan Asia Heart Hospital on its restructuring, Series C and cross-over financing

• Advised Liangyihui, an innovative Internet medical company focusing on the vertical field of oncology, on its Series C financing, Series C+ financing, ESOP, etc.

• Advised Liangyihui, an innovative Internet medical company focusing on the vertical field of oncology, on its investment in a clinical data capturing and management software developer

• Advised Liangyihui, an innovative Internet medical company focusing on the vertical field of oncology, on its establishment of a joint venture

• Advised Brain Doctor Group on its Series A financing

• Advised Extong, an Internet medical enterprise, on its restructuring and financing

• Advised DIMA Holdings on its acquisition of three nursing homes in Hangzhou

• Advised Haier Capital on its acquisition of Shanghai Yongci Rehabilitation Hospital

• Advised Haier Capital on its acquisition of Honghao Nursing Home

• Advised China Minsheng Investment Group on its acquisition of Shifang No.2 Hospital

• Advised China Minsheng Investment Group on its acquisition of Chongzhou No.2 People’s Hospital

• Advised China Minsheng Investment Group on its acquisition of Shandong Municipal Hospital Holding Group

• Advised China Minsheng Investment Group on its acquisition of Qingdao Jingkang Hospital

• Advised China Minsheng Investment Group on its acquisition of Yugan County Chudong Hospital

• Advised China Minsheng Investment Group on its acquisition of Huzhou Nursing Home

• Advised China Minsheng Investment Group on its acquisition of a hospital in Changde

• Advised China Minsheng Investment Group on its acquisition of China Coal Mine Construction General Hospital

• Advised China Minsheng Investment Group on its acquisition of two private hospitals in Yancheng

IPO and Other Capital Markets Matters

• Project Zero, IPO of a medical data company on NASDAQ

• Project Elegant, IPO of a biotech company on NASDAQ

• Project Tesla, IPO of a biotech company on its H-share listing under Chapter 18A of the Main Board Listing Rules

• Project Yuanzhi, IPO of an Internet medical company on its A-share listing on GEM

• Advised Hanvo Safety Products on its A-share listing on GEM

• Advised Jiangsu Times Clothing on its A-share listing on main board

• Advised Shoulder Electronics on its A-share listing on STAR market

• Advised Jiangsu Haili Wind Power Equipment Technology on its A-share listing on GEM

• Advised Motion Magic on its A-share listing

• Advised China Lodging Group on its listing on NASDAQ

• Advised EAST TOP Group on its A-share listing

• Advised Joyu Group (lvmama) on its listing on HKEX

• Advised Ping An Trust on its investment in the privatization of WuXi PharmaTech from NYSE

• Advised Reyoung Pharmaceutical Co., Ltd. on its delisting from SGX, restructuring and listing in PRC capital market

• Advised an investor on its acquisition financing for privatization of Wanxiang International Group from SGX

• Advised an investor on its acquisition financing for privatization of RAE SYSTEMS from NASDAQ

• Advised Ping An Trust on its acquisition of 47.4% equity in AutoHome for USD 1.6 billion

• Advised Reach Surgical Inc., a surgical high-tech medical device enterprise, and its founders on the buy-out transaction led by Boyu Capital

• Advised Ping An Trust and Haitian Energy on the investment of RMB 6 billion in hydropower projects

• Advised Guiyang Financial Holdings, a subsidiary of Zhongtian Urban Development Co., Ltd. (A-share listed) on its acquisition of 66.67% equity in Haiji Securities for RMB 3 billion

• Advised Ping An Securities on its investment in a NASDAQ listed company

• Advised Zhonghong Holdings on its acquisition of Abercrombie & Kent

• Advised Zhonghong Holding on its acquisition of Peninsula

• Advised Shanghai Feilo Co., Ltd (A-share listed) on its acquisition of Shenglan Company

• Advised Shanghai Feilo Co., Ltd (A-share listed) on its acquisition of ACDelco

• Advised Sunshine Insurance Group on its investment in a NASDAQ listed company

• Advised Nanjing Environmental Frontier Company on its listing on NEEQ

• Advised Quansheng Logistics Ltd. on its listing on NEEQ

• Advised Anhorn Environmental Technology on its financing and application for NEEQ listing

• Advised Fancyedu on its financing and application for NEEQ listing

• Advised Hangzhou Yuhang Transportation Group Co., Ltd. on its issuance of medium-term notes in 2012 (RMB 2 billion)

• Advised Zunyi Taiye Co., Ltd. on its issuance of short-term financing bonds in 2012 (RMB 300 million)

• Advised Harbour City Development Group on its issuance of medium-term note in 2016 (on-going)

• Advised Qiangsheng Holding Company on its issuance of short-term bonds in interbank market in 2014 (RMB 425 million)

• Advised Qiangsheng Holding Company on its issuance of short-term bonds in interbank market in 2015 (RMB 500 million)

• Advised Qiangsheng Holding Company on its issuance of short-term bonds in interbank market in 2016 (on-going)

• Advised Hongrun Group on its issuance of short-term bonds in 2012 (RMB 220 million)

• Advised Qiangsheng Holding Company on its issuance of short-term bonds in 2012 (RMB 800 million)

• Advised Ningbo Electric Group on its issuance of short-term bonds in interbank market in 2011 (RMB 600 million)

• Advised an animal nutrient company on its issuance of medium-term notes and short-term bonds in interbank market in 2012 (RMB 350 million)

• Advised an animal nutrient company on its issuance of medium-term notes and short-term bonds in interbank market in 2010 (RMB 600 million)

• Advised Zhejiang Guangtian Riyue Group Co., Ltd. on its registration and issuance of the first phase of short-term financing bonds in 2012 (RMB 600 million)

• Advised Shanghai Dragon Group on its issuance of short-term bonds in interbank market in 2010 (RMB 500 million)

• Advised Harbour City Development Group on its issuance of short-term bonds and private debt

• Advised Ping An Trust on its investment in Zhongshan Environmental Protection Industry Company Limited

• Advised Ping An Trust on its investment in Sichuan Zhongming Environmental Protection Co., Ltd.

• Advised Ping An Trust on its investment in Hubei Zhongyou Youyi Environmental Protection Co., Ltd.

• Advised Ping An Trust on its investment in Zhe Jiang Wuhuan Titanium Industry Co., Ltd.

• Advised Ping An Trust on its investment in Shanghai Future Broadband Technology and Application Engineering Research Center Co., Ltd.

• Advised Ping An Trust on its investment in an energy saving company in Weifang Shandong

• Advised Fengshan Investment and Lujiazui Trust on its investment in the IDC room project in Beijing and Shenzhen

• Advised Morgan Stanley and Goldman Sachs on its China Lodging Group’s IPO on NASDAQ

• Advised Instrument Electric Group on its acquisition of overseas enterprises

• Advised Maike Group on its private equity financing in the amount of up to USD 100 million from Softbank

• Advised China Lodging Group on its private equity financing from Colony Capital

• Advised a nuclear equipment manufacturer on its private equity financing

• Advised Smart Cargo on its share transfer, restructuring and establishment of joint venture with CJ Korea Express

Funds Formation

• Advised WuXi PharmaTech on its PE fund formation

• Advised China Pacific Asset on its establishment of its PE fund

• Advised Shanghai Culture Industry Fund on its investment in a PE fund

• Advised Shanghai Aviation Industry Equity Investment Fund Partnership Enterprise (limited partnership) on its fund formation

• Advised Shanghai Hongyu Aviation Industry Equity Investment Partnership (limited partnership) on its fund formation

• Advised Haoyue Capital on its USD fund formation

• Advised Jinjiang International Investment Group and Sunshine Exchange on their registering for a PE investment fund manager and the establishment of an industrial fund

• Advised the government of Minhang District guiding fund on its legal due diligence with respect to the managers of RMB funds Lenovo, Joint Fortune, SAIF, etc.

• Advised Shanghai Venture Capital on its legal due diligence with respect to the managers of Guohong Fund and Zhonghui Jinjiu Fund

• Advised Shanghai Airport Group on its establishment of an investment platform

• Advised Pudong Technology Innovation on its establishment of an investment platform

• Advised Ping An Group on its establishment of an insurance capital investment platform

• Advised China Resources Group and Shanghai New Hongqiao Group on their establishment of a joint venture fund named China Resources New Hongqiao Medical Industry Investment Fund

• Advised China Minsheng Investment on its establishment of two domestic medical funds

• Advised New Huangpu, Warburg Pincus and Vanke Real Estate on its the establishment of a joint venture PE fund

• Advised Jingruiluode City Update Fund on its fund formation, services including document drafting, negotiation, etc.

• Advised Hechun Investment on its establishment of contract-based real estate fund, services including drafting the fund documents, assisting in fund raising and filing of the fund

• Advised Jingrui Real Estate on its establishment of a RMB fund and an offshore USD fund

• Advised the managers of Shanghai Zhixing Fund, Yuanyang Zhixing Fund and Zhongtian Holding Group Fund on their registration with the AMAC and record-filing of the funds

• Advised Lituo Ningbo on its onshore and offshore parallel fund formation

• Advised Ctrip on its establishment of Feima Fund by structure advisory and document drafting

• Advised Yang Zhengyu and Yuan Yue on their establishment of Feima Fund

Commodities

• Advised the PRC trading house of BTG Pactual on Chinese legal affairs

• Advised the PRC trading house of Trafigura on Chinese legal affairs

• Advised the PRC trading house of JP Morgan on Chinese legal affairs

• Advised the PRC trading house of Mercuria on Chinese legal affairs

• Advised the PRC trading house of Koch on Chinese legal affairs

• Advised Jiangtong Corporation, Wanxiang Resources Co., Ltd., Maike Group and Easthope Group on legal affairs

  
  

Corporate Finance

• Advised Banque de l'Indochine, Standard Chartered Bank, Development Bank of Singapore, Deutsche Bank, ABN-AMRO BANK, Nanyang Commercial Bank, KBC Group, First Sino Bank, Shanghai Pudong Development Bank, Bank of China, China Construction Bank, China Minsheng Bank, Ping An Bank, China Merchants Bank, Bank of Shanghai and Shanghai Rural Commercial Bank on their trade financing, supply chain financing, syndicated loan, standard templates drafting, financial derivatives product, ISDA, etc.

• Advised ZQFAE in respect of China’s first securitization of earnings arising from housing provident fund

• Advised Minsheng Leasing on its Reits projects

• Advised Minsheng Bank on its Beijing Haidian affordable housing ABS project

• Advised Minsheng Bank on its Beijing Chaoyang affordable housing ABS project

• Advised Minsheng Bank Guangzhou and Huizhou branches on their CLO project

• Advised Minsheng Bank Beijing branch on its Weikai ABS project

• Advised tourist area in the western region on its right to charge ABS project

• Advised Huizhou delivery shuttle bus on its toll right ABS project

• Advised Baic Group on its repurchase ABS project

• Advised Beijing Agricultural Bank on its clearing center rent ABS project

• Advised Ping An on its investment in a real estate project in Australia to set up a special dividend income fund

• Advised Ping An on its establishment of Shanghai Xiangzhao Limited partnership fund

• Advised Ping An Life and Ping An Property Insurance on legal opinions and other legal documents required by the CIRC

• Advised CMIG on its establishment of two domestic medical fund projects

• Advised Ping An Trust on its set up trust to purchase bonds issued by Deutsche Bank England branch through QDII

• Advised Ping An Trust on its set up trust to purchase bonds issued by Citibank through QDII

• Advised Ping An Trust on its set up trust to purchase bonds issued by UBS through QDII

• Advised Ping An Trust on its set up trust to purchase bonds issued by Nomura through QDII

• Advised JD Fiance and Hony Capital on setting up trust plan of consumer loan trust scheme

• Advised Bank of Shanghai on its RMB 1.92 billion cross-border acquisition finance in real property project

• Advised Bank of Shanghai on its participation in a series of asset management and limited liability partnerships

• Advised China Resources SZITIC Trust Co., Ltd. on its participation in a series of trusts and investment in limited partnership projects

• Advised Ping An Trust on its participation in a series of trusts and investment in limited partnership projects

• Advised AVIC on its domestic and overseas ship financing lease project

Real Estate and Hotel

• Advised Jing Rui real estate on establishment of domestic RMB funds and the foreign dollar fund in the client’s acquisition of real estate

• Advised a real estate development company in Kunming, Yunnan on its financing by an offshore investment fund of Standard Chartered

• Advised First Sino Bank on its purchase of Shanghai financial plaza office

• Advised Yaoda Real Estate on its acquisition of a villa property management project in Qingpu, Shanghai

• Advised Cifi Group on its acquisition of a company in Shanghai

• Advised China Minsheng Jiaye Investment Corp., Ltd. on its acquisition of a company in Chengdu

• Advised China Minsheng Drawin Company on its acquisition of industrial real estate projects

• Advised SRE Group on its acquisition of a land banking company

• Advised China Resources SZITIC Trust Co., Ltd. on its participation in trust financing of multiple real estate projects

• Advised Bank of Shanghai on its participation in structured financing of multiple real estate projects

• Advised Yoda Real Estate on its hotel management consultation project with the InterContinental Hotel

• Advised a real estate company in Yunnan on its hotel management cooperation project with four of the Hilton brand hotels

• Advised China Minsheng Jiaye Investment Corp., Ltd. on its hotel management cooperation project with a top brand hotel owned by Marriott

• Zhong Lun Advises TIMES on its IPO on the Main Board of Shenzhen Stock Exchange